

Pulmonary Hypertension in the Intensive Care Unit (ICU) - Swiss Survey 1

Submission date 06/09/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 28/10/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 28/10/2010	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Urs Wenger

Contact details
University Hospital Zürich
Rämistrasse 100
Zürich
Switzerland
8091

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
A prospective multicentre study to investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension in the Intensive Care Unit (ICU)

Acronym
PHICUSS1

Study objectives

To investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension (PH) of any cause in the setting of surgical, medical or interdisciplinary Intensive Care Units (ICUs) of primary, secondary and tertiary Swiss hospitals.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was not required for this study.

Study design

Prospective multicentre study

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Pulmonary hypertension

Interventions

The current characteristics, local facilities, diagnostic and therapeutic attitude against PH of the participating ICUs are assessed prior to study beginning by a questionnaire (hospital form).

During the study period all consecutive patients admitted to ICU for any reason are screened for presence or suspicion of PH. If PH is present or suspected the most probable causes, diagnostic and therapeutic attitude, clinical, laboratory, haemodynamic data (if measured) and 30 days survival will be assessed by a questionnaire (patient form).

Participating centres are asked to complete the hospital form only once, before study begin. Thereafter, during the enrolment period all patients admitted to the participating ICU are screened by use of the patient form. Only if PH is present, suspected or disclosed at ICU admission, or if risk factors for PH were present, additional information will be requested.

Data collection will be performed online using an electronic form of the data collection sheet.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Prevalence of PH of any cause in the setting of surgical, medical or interdisciplinary ICUs. During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.

Key secondary outcome(s))

1. Causes of PH in the ICU setting
2. Diagnostic and therapeutic approach to PH by Swiss ICU physicians
3. 30 day outcome of patients admitted to ICU with suspected or confirmed PH

During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.

Completion date

30/09/2009

Eligibility

Key inclusion criteria

All consecutive patients (no age limit or gender restrictions) admitted to ICU for any reason

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

01/09/2009

Date of final enrolment

30/09/2009

Locations

Countries of recruitment

Switzerland

Study participating centre

University Hospital Zürich

Zürich

Switzerland

8091

Sponsor information

Organisation

Swiss Society of Pulmonary Hypertension (Switzerland)

ROR

<https://ror.org/02c518c71>

Funder(s)

Funder type

Research organisation

Funder Name

Swiss Society of Intensive Care Medicine (Switzerland)

Funder Name

Actelion Pharma Schweiz AG (Switzerland)

Funder Name

Lung League Ticino (Switzerland)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes